Cargando…

Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer

The association between germline BRCA1 and BRCA2 pathogenic variants (mutations: gBRCAm) and ovarian cancer risk is well established. Germline testing alone cannot detect somatic BRCA1/2 pathogenic variants (sBRCAm), which is calculated based on the proportion of tumor BRCAm (tBRCAm) from tumor samp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oda, Katsutoshi, Aoki, Daisuke, Tsuda, Hitoshi, Nishihara, Hiroshi, Aoyama, Hisanori, Inomata, Hyoe, Shimada, Muneaki, Enomoto, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807512/ https://www.ncbi.nlm.nih.gov/pubmed/36254756 http://dx.doi.org/10.1111/cas.15518

Ejemplares similares

Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study
por: Yoshihara, Kosuke, et al.
Publicado: (2020)

An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group
por: Shigeta, Shogo, et al.
Publicado: (2023)

Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)
por: Kobayashi, Yusuke, et al.
Publicado: (2022)

An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
por: Shimada, Muneaki, et al.
Publicado: (2023)

The Prevalence and Diagnostic Ratio of Familial Hypercholesterolemia (FH) and Proportion of Acute Coronary Syndrome in Japanese FH Patients in a Healthcare Record Database Study
por: Teramoto, Tamio, et al.
Publicado: (2020)

Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
por: Asano, Hiroshi, et al.
Publicado: (2022)

Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
por: Sekine, Masayuki, et al.
Publicado: (2021)

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study
por: Yoshihara, Kosuke, et al.
Publicado: (2023)

Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer
por: Hirasawa, Akira, et al.
Publicado: (2017)

BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art
por: Sekine, Masayuki, et al.
Publicado: (2021)

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial
por: Koba, Shinji, et al.
Publicado: (2020)

Actual state of “triple therapy” for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database
por: Abe, Daisuke, et al.
Publicado: (2021)

Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic
por: Matsuo, Koji, et al.
Publicado: (2021)

Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2)
por: Tokunaga, Hideki, et al.
Publicado: (2021)

Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing
por: Hirotsu, Yosuke, et al.
Publicado: (2015)

Surgically treated cervical cancer in a high-risk group in the era of the 2018 FIGO staging schema: a nationwide study
por: Shigeta, Shogo, et al.
Publicado: (2023)

Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome
por: Kaneyasu, Tomoko, et al.
Publicado: (2020)

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
por: Sekine, Masayuki, et al.
Publicado: (2022)

Japanese periodical nationwide epidemiologic survey of aberrant portal hemodynamics
por: Ohfuji, Satoko, et al.
Publicado: (2019)

Ovarian conservation for young women with clinical stage IB–IIB cervical cancer in Japan
por: Matsuo, Koji, et al.
Publicado: (2017)

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference
por: Jang, Ji Yon Agnes, et al.
Publicado: (2017)

High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer
por: Iwadate, Reiko, et al.
Publicado: (2014)

BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ
por: Liu, Yan, et al.
Publicado: (2019)

Federated analysis of BRCA1 and BRCA2 variation in a Japanese cohort
por: Casaletto, James, et al.
Publicado: (2022)

Pulmonary metastasis secondary to abiraterone‐resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case
por: Izawa, Mizuki, et al.
Publicado: (2020)

The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study
por: Mitamura, Takashi, et al.
Publicado: (2021)

Mutation status of RAD51C,PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations
por: Sato, Katsutoshi, et al.
Publicado: (2017)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas
por: Miyamoto, Morikazu, et al.
Publicado: (2017)

Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
por: Hayano, Takahide, et al.
Publicado: (2014)

Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study
por: Gupta, Sudeep, et al.
Publicado: (2021)

Revisiting Shimoda's “Shuuchaku-Kishitsu” (Statothymia): A Japanese View of Manic-Depressive Patients
por: Tsuda, Hitoshi
Publicado: (2011)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study
por: Toss, Angela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qkbhjci1sonn5fphqankhdv9ho